Welcome to Dividend.com
Please help us personalize your experience.
Select the one that best describes you

Loncar Cancer Immunotherapy ETF

etf
CNCR
Dividend policy
Suspended
Price as of:
$29.9 +0.35 +0%
primary theme
Health Care Sector Equity
CNCR (ETF)

Loncar Cancer Immunotherapy ETF

Dividend policy
Suspended
Price as of:
$29.9 +0.35 +0%
primary theme
Health Care Sector Equity
CNCR (ETF)
Loncar Cancer Immunotherapy ETF
Dividend policy
Suspended
Price as of:
$29.9 +0.35 +0%
primary theme
Health Care Sector Equity

CNCR - Snapshot

Vitals

  • YTD Return 27.6%
  • 3 Yr Annualized Return 1.5%
  • 5 Yr Annualized Return -0.5%
  • Net Assets $38.3 M
  • Holdings in Top 10 47.2%

52 WEEK LOW AND HIGH

$29.55
$15.99
$29.90

Expenses

OPERATING RELATED FEES

  • Expense Ratio 0.79%

SALES FEES

  • Front Load N/A
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 53.00%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

  • Standard (Taxable) N/A
  • IRA N/A

Fund Classification

  • Primary Theme Health Care Sector Equity
  • Fund Type Exchange Traded Fund
  • Investment Style Health

Compare CNCR to Popular Health Care Sector Equity Funds

Overview

Next Dividend

Income Profile

Income Risk

Returns Profile

Allocations

Expenses

About

Dividend.com Ratings*

$106.08

-0.29%

$12.74 B

1.20%

$1.27

blocked
blocked
blocked

10.56%

-

Compare CNCR to Popular Health Care Sector Equity ETFs

Overview

Next Dividend

Income Profile

Income Risk

Returns Profile

Allocations

Expenses

About

Dividend.com Ratings*

$108.44

-0.37%

$22.44 B

1.51%

$1.65

blocked
blocked
blocked

6.46%

-

$212.12

-0.21%

$12.74 B

1.20%

$2.55

blocked
blocked
blocked

10.63%

-

$138.95

+0.51%

$8.76 B

0.22%

$0.30

blocked
blocked
blocked

15.30%

-

$307.95

-0.53%

$8.15 B

0.27%

$0.84

blocked
blocked
blocked

16.51%

-

$126.82

+0.60%

$5.33 B

0.08%

$0.11

blocked
blocked
blocked

33.34%

-

CNCR - Profile

Distributions

  • YTD Total Return 27.6%
  • 3 Yr Annualized Total Return 1.5%
  • 5 Yr Annualized Total Return -0.5%
  • Capital Gain Distribution Frequency N/A
  • Net Income Ratio -0.32%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name
    Loncar Cancer Immunotherapy ETF
  • Fund Family Name
    Loncar Investments
  • Inception Date
    Oct 13, 2015
  • Shares Outstanding
    1450000
  • Share Class
    N/A
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    Austin Wen

Fund Description

The index is composed of the common stock of approximately 25 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. Normally it will invest at least 80% of its total assets in the component securities of the index. The fund is non-diversified.


CNCR - Performance

Return Ranking - Trailing

Period CNCR Return Category Return Low Category Return High Rank in Category (%)
YTD 27.6% -6.1% 122.9% 11.80%
1 Yr 33.3% -1.4% 132.6% 13.75%
3 Yr 1.5%* 0.8% 40.7% 98.60%
5 Yr -0.5%* -0.7% 29.6% 99.29%
10 Yr N/A* 8.1% 19.7% N/A

* Annualized

Return Ranking - Calendar

Period CNCR Return Category Return Low Category Return High Rank in Category (%)
2019 24.2% 3.8% 63.8% 27.59%
2018 -20.6% -49.7% 21.5% 95.62%
2017 12.0% -59.8% 54.4% 72.59%
2016 -25.6% -36.6% 11.6% 94.57%
2015 N/A -62.4% 27.9% N/A

Total Return Ranking - Trailing

Period CNCR Return Category Return Low Category Return High Rank in Category (%)
YTD 27.6% -6.1% 122.9% 11.80%
1 Yr 33.3% -6.5% 132.6% 13.75%
3 Yr 1.5%* -0.3% 40.7% 97.20%
5 Yr -0.5%* -0.7% 29.6% 99.29%
10 Yr N/A* 8.1% 19.7% N/A

* Annualized

Total Return Ranking - Calendar

Period CNCR Return Category Return Low Category Return High Rank in Category (%)
2019 24.2% 3.8% 63.8% 27.59%
2018 -20.6% -25.3% 22.2% 96.35%
2017 12.0% -10.8% 54.4% 80.00%
2016 -25.6% -36.6% 11.6% 97.67%
2015 N/A -16.6% 27.9% N/A

CNCR - Holdings

Concentration Analysis

CNCR Category Low Category High CNCR % Rank
Net Assets 38.3 M 3.74 M 46 B 80.23%
Number of Holdings 31 24 426 95.35%
Net Assets in Top 10 18.1 M 952 K 19.6 B 76.16%
Weighting of Top 10 47.21% 14.0% 75.7% 19.77%

Top 10 Holdings

  1. Replimune Group Inc 6.36%
  2. BeiGene Ltd ADR 5.68%
  3. BioNTech SE ADR 5.51%
  4. Trillium Therapeutics Inc 5.20%
  5. CRISPR Therapeutics AG 4.82%
  6. Fate Therapeutics Inc 4.66%
  7. Compugen Ltd 4.16%
  8. Compugen Ltd 4.16%
  9. Compugen Ltd 4.16%
  10. Compugen Ltd 4.16%

Asset Allocation

Weighting Return Low Return High CNCR % Rank
Stocks
99.97% 61.47% 102.50% 15.70%
Cash
0.02% -0.01% 32.46% 84.30%
Preferred Stocks
0.00% 0.00% 6.63% 43.60%
Other
0.00% -2.50% 6.07% 51.16%
Convertible Bonds
0.00% 0.00% 0.06% 33.14%
Bonds
0.00% 0.00% 16.11% 34.88%

Stock Sector Breakdown

Weighting Return Low Return High CNCR % Rank
Healthcare
100.00% 61.81% 100.00% 14.53%
Utilities
0.00% 0.00% 0.00% 31.98%
Technology
0.00% 0.00% 15.86% 43.02%
Real Estate
0.00% 0.00% 6.03% 36.63%
Industrials
0.00% 0.00% 5.94% 38.37%
Financial Services
0.00% 0.00% 3.31% 59.30%
Energy
0.00% 0.00% 0.00% 31.98%
Communication Services
0.00% 0.00% 4.69% 35.47%
Consumer Defense
0.00% 0.00% 34.31% 37.79%
Consumer Cyclical
0.00% 0.00% 1.09% 37.21%
Basic Materials
0.00% 0.00% 2.60% 54.07%

Stock Geographic Breakdown

Weighting Return Low Return High CNCR % Rank
US
58.09% 47.91% 99.98% 97.67%
Non US
41.88% 0.00% 43.79% 1.16%

CNCR - Expenses

Operational Fees

CNCR Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.79% 0.08% 25.14% 66.87%
Management Fee 0.79% 0.00% 1.25% 70.35%
12b-1 Fee 0.00% 0.00% 1.00% 5.33%
Administrative Fee N/A 0.03% 0.40% N/A

Sales Fees

CNCR Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 3.50% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

CNCR Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 2.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

CNCR Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 53.00% 0.70% 252.00% 71.78%

CNCR - Distributions

Dividend Yield Analysis

CNCR Category Low Category High CNCR % Rank
Dividend Yield 0.00% 0.00% 3.15% 44.19%

Dividend Distribution Analysis

CNCR Category Low Category High Category Mod
Dividend Distribution Frequency Annually Annually Quarterly Annually

Net Income Ratio Analysis

CNCR Category Low Category High CNCR % Rank
Net Income Ratio -0.32% -2.53% 2.53% 69.46%

Capital Gain Distribution Analysis

CNCR Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Semi-Annually Annually

Dividend Payout History

View More +

CNCR - Fund Manager Analysis

Managers

Austin Wen


Start Date

Tenure

Tenure Rank

Dec 31, 2018

1.84

1.8%

Austin Wen, CFA has seven years of investment management experience. Mr. Wen is a Portfolio Manager at Vident, specializing in portfolio management and trading of equity portfolios and commodities based portfolios, as well as risk monitoring and investment analysis. Previously, Mr. Wen was an analyst for Vident Financial, working on the development and review of investment solutions. He began his career as a State Examiner for the Georgia Department of Banking and Finance. Mr. Wen obtained a BA in Finance from the University of Georgia and holds the Chartered Financial Analyst designation.

Rafael Zayas


Start Date

Tenure

Tenure Rank

Jun 19, 2020

0.37

0.4%

Rafael Zayas, CFA, is a portfolio manager. Mr. Zayas became SVP, Head of Portfolio Management and Trading in June 2020. From 2017 to 2020, he was a Senior Portfolio Manager – International Equity at Vident and has over 15 years of experience that includes managing international equity portfolios, including in emerging and frontier markets. Prior to joining Vident, he was a Portfolio Manager – Direct Investments for seven years at Russell Investments, a global asset manager, where he co-managed more than $4 billion in quantitative strategies across global markets, including the Russell Strategic Call Overwriting Fund, a mutual fund. Mr. Zayas also helped Russell Investments launch its sponsored ETF initiative and advised on index methodologies. Prior to joining Russell Investments, Mr. Zayas was a Portfolio Manager – Equity Indexing at Mellon Capital Management, where he managed assets for internationally listed global equity ETFs. Mr. Zayas graduated with a B.S. in Electrical Engineering from Cornell University and obtained a Certificate in Computational Finance and Risk Management from the University of Washington. He also attained the Chartered Financial Analyst designation in 2010.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.09 23.14 7.28 20.52

Continue to site >
Trending ETFs